The National Academy for State Health Policy (NASHP) will hold a webinar on June 16, 2026, from 3–4 p.m. ET focusing on payment reform strategies for rural health settings. The session will explore collaborative learning opportunities around alternative payment models designed for rural providers. Rural health care delivery intersects with Medicaid managed care in states where MCOs serve rural populations or where rural providers participate in value-based payment arrangements.
Why it mattersMedicaid MCOs operating in rural markets need to understand emerging payment reform models that accommodate lower patient volumes, geographic challenges, and the unique economic pressures facing rural safety-net providers.
Managed Care · Finance
Health economist William Padula argues that high-cost gene therapies, including treatments costing $2 million or more, require new financing models to enable patient access. The commentary asserts that the barrier to deploying curative therapies is not scientific but financial and infrastructural. Padula contends that existing payment systems are ill-equipped to handle the upfront costs of one-time curative treatments. The piece calls for innovative financing mechanisms to bridge the gap between therapeutic breakthroughs and patient access.
Why it mattersMedicaid managed care organizations face growing pressure to cover costly gene therapies while managing capitated budgets, making alternative payment models and risk-sharing arrangements operationally critical.
Pharmacy · Managed Care · Finance
Eli Lilly's June 1 deadline for hospitals to submit claims data to maintain 340B drug discounts has passed without HRSA intervention. Hospitals that failed to comply with Lilly's data submission requirements will lose access to discounted pricing on covered drugs. HRSA has not responded to requests from hospital and pharmacy groups to intervene in the dispute. The action affects hospitals participating in the 340B program that purchase Lilly medications.
Why it mattersMedicaid MCOs with contract pharmacy arrangements or safety-net hospital partnerships may see increased drug costs if 340B-eligible hospitals lose discounts and shift utilization or seek higher reimbursement rates.
Pharmacy · Managed Care
Three U.S. hospitals and emergency departments closed in early 2026, compared to 13 at the same point in 2025. Total closures in 2025 reached 23, nearly matching the 25 reported in 2024. The article suggests the early 2026 slowdown may not indicate structural improvement in hospital financial stability. The trend continues a multi-year pattern of hospital closures driven by financial pressures.
Why it mattersHospital closures reduce network capacity and can trigger MCO adequacy requirements for alternative contracting, particularly in rural and underserved areas where replacement capacity is limited.
Managed Care
The American Diabetes Association's annual conference featured industry discussions on the competitive landscape for GLP-1 obesity medications and identified clinical blind spots in diabetes care delivery. The conference addressed how pharmaceutical competition is shaping market access and pricing dynamics for widely-used medications including semaglutide and tirzepatide. For Medicaid managed care organizations, these developments directly affect formulary strategy, prior authorization protocols, and budget forecasting for one of the fastest-growing drug spending categories.
Why it mattersMedicaid MCOs face escalating costs and utilization management challenges for GLP-1 medications, which represent significant budget pressure while state coverage policies and clinical criteria continue to evolve rapidly.
Managed Care · Pharmacy
President Trump announced Friday that TrumpRx.gov will add 160 prescription medications to its direct-to-consumer platform, bringing the total to over 800 drugs available at discounted prices. This marks the second expansion of the initiative in two months. The platform sells drugs directly to consumers, bypassing traditional pharmacy channels. The announcement did not specify which drugs were added or provide details about pricing structures or manufacturer participation.
Why it mattersFederal direct-to-consumer drug sales could affect Medicaid managed care pharmacy benefit management, prescription volume through contracted pharmacies, and MCO pharmacy rebate arrangements if beneficiaries shift purchasing patterns.
Pharmacy · Managed Care
A new Commonwealth Fund study found that one in five U.S. adults were denied doctor-recommended care, leading to deteriorating health outcomes and financial strain. The research highlights increasing patient frustration with claims review processes and prior authorization barriers. Insurers maintain their utilization management protocols are medically appropriate. The findings come as regulatory scrutiny of managed care denial practices intensifies at both federal and state levels.
Why it mattersRising denial rates increase the likelihood of state and federal regulatory action targeting MCO utilization management practices, including prior authorization reform, appeals transparency requirements, and potential network adequacy enforcement.
Managed Care